Wealthfront Advisers LLC Buys Shares of 10,596 DaVita Inc. $DVA

Wealthfront Advisers LLC purchased a new position in shares of DaVita Inc. (NYSE:DVA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,596 shares of the company’s stock, valued at approximately $2,357,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Root Financial Partners LLC boosted its stake in DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares during the last quarter. Caitlin John LLC bought a new stake in shares of DaVita in the 4th quarter worth about $34,000. Sankala Group LLC acquired a new stake in shares of DaVita in the 4th quarter valued at about $39,000. Canada Pension Plan Investment Board bought a new position in shares of DaVita during the second quarter worth about $43,000. Finally, Kestra Advisory Services LLC bought a new position in shares of DaVita during the fourth quarter worth about $45,000. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 1.0%

DVA stock opened at $175.54 on Friday. The stock has a market cap of $11.20 billion, a PE ratio of 14.36, a price-to-earnings-growth ratio of 0.59 and a beta of 0.88. The firm’s 50-day simple moving average is $215.64 and its 200 day simple moving average is $181.58. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same period in the previous year, the business posted $2.95 EPS. DaVita’s revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts forecast that DaVita Inc. will post 14.57 EPS for the current fiscal year.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.90% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on DVA shares. Barclays boosted their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Raymond James Financial set a $220.00 price target on DaVita in a report on Friday, August 7th. TD Cowen raised DaVita from a “hold” rating to a “buy” rating and upped their price target for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 price objective on shares of DaVita in a report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, DaVita currently has a consensus rating of “Hold” and an average target price of $221.75.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.